TURKU, FINLAND: Faron Pharmaceuticals Ltd. (AIM: FARN), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today announced that its Chief Executive Officer (CEO) Dr. Markku Jalkanen, who turns 70 later in 2024, has informed the Board of Directors of his wish…
All posts tagged Faron Pharmaceuticals
Juho Jalkanen appointed Chief Operating Officer of Faron Pharmaceuticals
TURKU, FINLAND: Faron Pharmaceuticals Ltd announced the appointment of Juho Jalkanen, M.D., Ph.D., as Chief Operating Officer of the Company. Dr. Jalkanen will continue to be based in Turku, Finland and his appointment is effective immediately. In his new role, Dr. Jalkanen will lead business strategy and daily operations for Faron Pharmaceuticals. This includes oversight…
Faron receives €2.1 million loan, from Business Finland for Traumakine manufacturing
TURKU, FINLAND: Faron Pharmaceuticals Oy, the clinical stage biopharmaceutical company, announced plans to initiate a new state of the art process for the manufacturing of interferon (IFN) beta-1a. To support this, Faron has received a €2.1 million low interest rate loan from Business Finland, the governmental innovation financing agency of Finland. The loan funds will…
Faron Pharmaceuticals selected for €2.5 million grant from European Innovation Council
TURKU, FINLAND: Faron Pharmaceuticals Oy, the clinical stage biopharmaceutical company, has been selected to receive a €2.5 million grant from the European Innovation Council (EIC) Accelerator pilot scheme to progress the MATINS Study and related business activities. The EIC Accelerator pilot scheme supports top-class innovators, entrepreneurs, small companies and scientists with funding opportunities to support…